NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $105.17 -0.26 (-0.25%) Closing price 03:59 PM EasternExtended Trading$105.06 -0.11 (-0.11%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Edwards Lifesciences Stock (NYSE:EW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$103.07▼$106.5650-Day Range$84.18▼$107.1652-Week Range$74.66▼$108.00Volume3.92 million shsAverage Volume4.53 million shsMarket Capitalization$60.47 billionP/E Ratio59.42Dividend YieldN/APrice Target$109.88Consensus RatingModerate Buy Company Overview Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world. Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease. Bernard Zovighian became the company’s chief executive officer in 2023.AI Generated. May Contain Errors. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreEW MarketRank™: 3.017939034255 of 5 starsEdwards Lifesciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 721st out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 23 buy ratings, 3 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Edwards Lifesciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.96% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.96% in the coming year, from $3.01 to $3.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 59.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 59.42, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.58.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.64% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 0.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.76 News SentimentEdwards Lifesciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Edwards Lifesciences this week, compared to 8 articles on an average week.Search Interest14 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat Follows8 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,498,306.00 in company stock.Percentage Held by Insiders0.31% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesEdwards Lifesciences: Momentum Returns, But Valuation Warrants CautionNovember 18 at 10:31 AM | seekingalpha.comWells Fargo & Company Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) StockNovember 18 at 2:13 AM | americanbankingnews.comBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.November 18 at 1:00 AM | Paradigm Press (Ad)Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?November 16 at 10:54 AM | finance.yahoo.comAre Wall Street Analysts Predicting Edwards Lifesciences Stock Will Climb or Sink?November 16 at 10:30 AM | barchart.comEdwards Lifesciences (NYSE:EW) Price Target Raised to $121.00November 14, 2026 | americanbankingnews.comInsider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 619 Shares of Company StockNovember 11, 2026 | insidertrades.comInsider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 48,900 Shares of Company StockNovember 10, 2026 | insidertrades.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $85.26 on January 1st, 2026. Since then, EW stock has increased by 23.3% and is now trading at $105.1680. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) posted its earnings results on Wednesday, November, 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.06. Edwards Lifesciences's revenue was up 10.5% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Top institutional shareholders of Edwards Lifesciences include State Street Corp (4.62%), Ninety One UK Ltd (2.07%), Goldman Sachs Group Inc. (0.94%) and Assenagon Asset Management S.A. (0.47%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Daniel J Lippis, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Donald E Bobo Jr, Annette Bruls, Andrew M Dahl, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include NVIDIA (NVDA), Salesforce (CRM), Adobe (ADBE), Visa (V), Mastercard (MA), Broadcom (AVGO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/04/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 EW's financial health is in the Green zone, according to TradeSmith. EW has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees16,000Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$109.88 High Price Target$121.00 Low Price Target$85.00 Potential Upside/Downside+4.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$1.77 Trailing P/E Ratio59.42 Forward P/E Ratio30.93 P/E Growth2.86Net Income$1.07 billion Net Margins15.30% Pretax Margin21.46% Return on Equity16.06% Return on Assets12.36% Debt Debt-to-Equity Ratio0.05 Current Ratio4.60 Quick Ratio3.86 Sales & Book Value Annual Sales$6.07 billion Price / Sales9.97 Cash Flow$2.80 per share Price / Cash Flow37.56 Book Value$19.06 per share Price / Book5.52Miscellaneous Outstanding Shares575,000,000Free Float573,218,000Market Cap$60.47 billion OptionableOptionable Beta0.85 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:EW) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.